ArticleFrontiers in genetics2019
Ultra-Sensitive Automated Profiling of EpCAM Expression on Tumor-Derived Extracellular Vesicles.
Article in Frontiers in genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Advancements in extracellular vesicle research.Extracellular vesicle · 2026Article
- Extracellular Vesicles for Clinical Diagnostics: From Bulk Measurements to Single-Vesicle Analysis.ACS nano · 2025Review
- Liquid biopsies in cancer.Molecular biomedicine · 2025Review
- Precision Fabrication and Optimization of Nanostructures for Exosome Detection via Surface-Enhanced Raman Spectroscopy.Nanomaterials (Basel, Switzerland) · 2025Article
- Exosomes in Oral Diseases: Mechanisms and Therapeutic Applications.Drug design, development and therapy · 2025Review
- Recent Advancements in Imaging Techniques for Individual Extracellular Vesicles.Molecules (Basel, Switzerland) · 2024Review
- An aptamer-guided fluorescence polarisation platform for extracellular vesicle liquid biopsy.Journal of extracellular vesicles · 2024Article
- Harnessing exosomes as cancer biomarkers in clinical oncology.Cancer cell international · 2024Review
- Extracellular Vesicle Preparation and Analysis: A State-of-the-Art Review.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Global trend in exosome isolation and application: an update concept in management of diseases.Molecular and cellular biochemistry · 2024Review
- Optical Imaging of Single Extracellular Vesicles: Recent Progress and Prospects.Chemical & biomedical imaging · 2024Review
- Harnessing microRNA-enriched extracellular vesicles for liquid biopsy.Frontiers in molecular biosciences · 2024Review
- Exosomes in Bone Cancer: Unveiling their Vital Role in Diagnosis, Prognosis, and Therapeutic Advancements.Journal of Cancer · 2024Review
- Lung cancer cell-derived exosomes: progress on pivotal role and its application in diagnostic and therapeutic potential.Frontiers in oncology · 2024Review
- The functional and clinical roles of liquid biopsy in patient-derived models.Journal of hematology & oncology · 2023Review
- Monitoring of single extracellular vesicle heterogeneity in cancer progression and therapy.Frontiers in oncology · 2023Review
- Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy.Cancer cell · 2022Article
- Molecular mechanisms and clinical applications of exosomes in prostate cancer.Biomarker research · 2022Review
- Nanoplasmonic Sensor Approaches for Sensitive Detection of Disease-Associated Exosomes.ACS applied bio materials · 2021Review
- Exosome-Mediated Crosstalk Between Tumor and Tumor-Associated Macrophages.Frontiers in molecular biosciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Extracellular vesicles (EVs) are abundant in most biological fluids and considered promising biomarker candidates, but the development of EV biomarker assays is hindered, in part, by their requirement for prior EV purification and the lack of standardized and reproducible EV isolation methods. We now describe a far-field nanoplasmon-enhanced scattering (FF-nPES) assay for the isolation-free characterization of EVs present in small volumes of serum (< 5 µl). In this approach, EVs are captured with a cancer-selective antibody, hybridized with gold nanorods conjugated with an antibody to the EV surface protein CD9, and quantified by their ability to scatter light when analyzed using a fully automated dark-field microscope system. Our results indicate that FF-nPES performs similarly to EV ELISA, when analyzing EV surface expression of epithelial cell adhesion molecule (EpCAM), which has clinical significant as a cancer biomarker. Proof-of-concept FF-nPES data indicate that it can directly analyze EV EpCAM expression from serum samples to distinguish early stage pancreatic ductal adenocarcinoma patients from healthy subjects, detect the development of early stage tumors in a mouse model of spontaneous pancreatic cancer, and monitor tumor growth in patient derived xenograft mouse models of pancreatic cancer. FF-nPES thus appears to exhibit strong potential for the direct analysis of EV membrane biomarkers for disease diagnosis and treatment monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.